GSK pays $23 million up front for preclinical candidate
This article was originally published in Scrip
Executive Summary
Amplimmune has entered a broad alliance with GlaxoSmithKline to develop PD-1 targeting therapies for the treatment of cancer and other diseases. GSK will obtain exclusive worldwide rights to its lead product AMP-224 as well as other potential next-generation fusion proteins that target PD-1.